Peptide analogs in the therapy of prostate cancer

Andrew V Schally, Ana Maria Comaru-Schally, Artur Plonowski, Attila Nagy, Gabor Halmos, Zoltan Rekasi

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

The use of peptide analogs in the therapy of prostate cancer is reviewed. The preferred primary treatment of advanced androgen-dependent prostate cancer is presently based on the use of devot preparations of LH-RH agonists. This treatment is likewise recommended in patients with rising PSA levels after surgery or radiotherapy. LH-RH agonists with or without antiandrogens can be also utilized prior to or following various local treatments in patients with clinically localized prostate cancer and at high risk for disease recurrence. LH-RH antagonists like Cetrorelix are in clinical trials. However, most patients with advanced prostatic carcinoma treated by any modality of androgen deprivation eventually relapse. Treatment of relapsed androgen-independent prostate cancer remains a major challenge, but new therapeutic modalities are being developed based on antagonists of growth hormone-releasing hormone (GH-RH) and bombesin, which inhibit growth factors or their receptors. Another approach consists of cytotoxic analogs of LH-RH, bombesin, and somatostatin containing doxorubicin or 2-pyrrolinodoxorubicin, which can be targeted to receptors for these peptides found in prostate cancers and their metastases. These cytotoxic analogs inhibit growth of experimental androgen-dependent or -independent prostate cancers and reduce the incidence of metastases. A rational therapy with peptide analogs could be selected on the basis of receptors present in biopsy samples. The approaches based on peptide analogs should result in a more effective treatment for prostate cancer. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)158-166
Number of pages9
JournalProstate
Volume45
Issue number2
DOIs
StatePublished - Oct 16 2000
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Peptides
Gonadotropin-Releasing Hormone
Androgens
Bombesin
Therapeutics
Neoplasm Metastasis
Recurrence
Androgen Antagonists
Growth Hormone-Releasing Hormone
Peptide Receptors
Somatostatin
Doxorubicin
Intercellular Signaling Peptides and Proteins
Radiotherapy
Clinical Trials
Carcinoma
Biopsy
Incidence
Growth

Keywords

  • Agonists of LH-RH
  • Antagonists of LH-RH
  • Bombesin antagonists
  • GH-RH antagonists
  • Targeted cytotoxic analogs of LH-RH, bombesin, and somatostatin or cytotoxic peptide analogs

ASJC Scopus subject areas

  • Urology

Cite this

Schally, A. V., Comaru-Schally, A. M., Plonowski, A., Nagy, A., Halmos, G., & Rekasi, Z. (2000). Peptide analogs in the therapy of prostate cancer. Prostate, 45(2), 158-166. https://doi.org/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Peptide analogs in the therapy of prostate cancer. / Schally, Andrew V; Comaru-Schally, Ana Maria; Plonowski, Artur; Nagy, Attila; Halmos, Gabor; Rekasi, Zoltan.

In: Prostate, Vol. 45, No. 2, 16.10.2000, p. 158-166.

Research output: Contribution to journalArticle

Schally, AV, Comaru-Schally, AM, Plonowski, A, Nagy, A, Halmos, G & Rekasi, Z 2000, 'Peptide analogs in the therapy of prostate cancer', Prostate, vol. 45, no. 2, pp. 158-166. https://doi.org/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K
Schally, Andrew V ; Comaru-Schally, Ana Maria ; Plonowski, Artur ; Nagy, Attila ; Halmos, Gabor ; Rekasi, Zoltan. / Peptide analogs in the therapy of prostate cancer. In: Prostate. 2000 ; Vol. 45, No. 2. pp. 158-166.
@article{838986743a1b4068a0f2bd0204c064d2,
title = "Peptide analogs in the therapy of prostate cancer",
abstract = "The use of peptide analogs in the therapy of prostate cancer is reviewed. The preferred primary treatment of advanced androgen-dependent prostate cancer is presently based on the use of devot preparations of LH-RH agonists. This treatment is likewise recommended in patients with rising PSA levels after surgery or radiotherapy. LH-RH agonists with or without antiandrogens can be also utilized prior to or following various local treatments in patients with clinically localized prostate cancer and at high risk for disease recurrence. LH-RH antagonists like Cetrorelix are in clinical trials. However, most patients with advanced prostatic carcinoma treated by any modality of androgen deprivation eventually relapse. Treatment of relapsed androgen-independent prostate cancer remains a major challenge, but new therapeutic modalities are being developed based on antagonists of growth hormone-releasing hormone (GH-RH) and bombesin, which inhibit growth factors or their receptors. Another approach consists of cytotoxic analogs of LH-RH, bombesin, and somatostatin containing doxorubicin or 2-pyrrolinodoxorubicin, which can be targeted to receptors for these peptides found in prostate cancers and their metastases. These cytotoxic analogs inhibit growth of experimental androgen-dependent or -independent prostate cancers and reduce the incidence of metastases. A rational therapy with peptide analogs could be selected on the basis of receptors present in biopsy samples. The approaches based on peptide analogs should result in a more effective treatment for prostate cancer. (C) 2000 Wiley-Liss, Inc.",
keywords = "Agonists of LH-RH, Antagonists of LH-RH, Bombesin antagonists, GH-RH antagonists, Targeted cytotoxic analogs of LH-RH, bombesin, and somatostatin or cytotoxic peptide analogs",
author = "Schally, {Andrew V} and Comaru-Schally, {Ana Maria} and Artur Plonowski and Attila Nagy and Gabor Halmos and Zoltan Rekasi",
year = "2000",
month = "10",
day = "16",
doi = "10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K",
language = "English",
volume = "45",
pages = "158--166",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Peptide analogs in the therapy of prostate cancer

AU - Schally, Andrew V

AU - Comaru-Schally, Ana Maria

AU - Plonowski, Artur

AU - Nagy, Attila

AU - Halmos, Gabor

AU - Rekasi, Zoltan

PY - 2000/10/16

Y1 - 2000/10/16

N2 - The use of peptide analogs in the therapy of prostate cancer is reviewed. The preferred primary treatment of advanced androgen-dependent prostate cancer is presently based on the use of devot preparations of LH-RH agonists. This treatment is likewise recommended in patients with rising PSA levels after surgery or radiotherapy. LH-RH agonists with or without antiandrogens can be also utilized prior to or following various local treatments in patients with clinically localized prostate cancer and at high risk for disease recurrence. LH-RH antagonists like Cetrorelix are in clinical trials. However, most patients with advanced prostatic carcinoma treated by any modality of androgen deprivation eventually relapse. Treatment of relapsed androgen-independent prostate cancer remains a major challenge, but new therapeutic modalities are being developed based on antagonists of growth hormone-releasing hormone (GH-RH) and bombesin, which inhibit growth factors or their receptors. Another approach consists of cytotoxic analogs of LH-RH, bombesin, and somatostatin containing doxorubicin or 2-pyrrolinodoxorubicin, which can be targeted to receptors for these peptides found in prostate cancers and their metastases. These cytotoxic analogs inhibit growth of experimental androgen-dependent or -independent prostate cancers and reduce the incidence of metastases. A rational therapy with peptide analogs could be selected on the basis of receptors present in biopsy samples. The approaches based on peptide analogs should result in a more effective treatment for prostate cancer. (C) 2000 Wiley-Liss, Inc.

AB - The use of peptide analogs in the therapy of prostate cancer is reviewed. The preferred primary treatment of advanced androgen-dependent prostate cancer is presently based on the use of devot preparations of LH-RH agonists. This treatment is likewise recommended in patients with rising PSA levels after surgery or radiotherapy. LH-RH agonists with or without antiandrogens can be also utilized prior to or following various local treatments in patients with clinically localized prostate cancer and at high risk for disease recurrence. LH-RH antagonists like Cetrorelix are in clinical trials. However, most patients with advanced prostatic carcinoma treated by any modality of androgen deprivation eventually relapse. Treatment of relapsed androgen-independent prostate cancer remains a major challenge, but new therapeutic modalities are being developed based on antagonists of growth hormone-releasing hormone (GH-RH) and bombesin, which inhibit growth factors or their receptors. Another approach consists of cytotoxic analogs of LH-RH, bombesin, and somatostatin containing doxorubicin or 2-pyrrolinodoxorubicin, which can be targeted to receptors for these peptides found in prostate cancers and their metastases. These cytotoxic analogs inhibit growth of experimental androgen-dependent or -independent prostate cancers and reduce the incidence of metastases. A rational therapy with peptide analogs could be selected on the basis of receptors present in biopsy samples. The approaches based on peptide analogs should result in a more effective treatment for prostate cancer. (C) 2000 Wiley-Liss, Inc.

KW - Agonists of LH-RH

KW - Antagonists of LH-RH

KW - Bombesin antagonists

KW - GH-RH antagonists

KW - Targeted cytotoxic analogs of LH-RH, bombesin, and somatostatin or cytotoxic peptide analogs

UR - http://www.scopus.com/inward/record.url?scp=0033809968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033809968&partnerID=8YFLogxK

U2 - 10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

DO - 10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

M3 - Article

C2 - 11027415

AN - SCOPUS:0033809968

VL - 45

SP - 158

EP - 166

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 2

ER -